Post listing view on Supriya Lifescience IPO By Mr. Santosh Meena, Swastika Investmart Ltd
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Below is the Post listing view on Supriya Lifescience IPO by Mr. Santosh Meena, Head of Research, Swastika Investmart Ltd
In the last 3-5 years, the API and specialty chemical industry have been darling for investors, and we believe that this trend will continue for several years. As a result of the decent participation from investors, the IPO debuted at Rs 421 versus the issue price of Rs 274, a premium of 53%. In the long run, investors should hold the stock while those who applied for listing gains can keep a stop loss of Rs 380 on a closing basis. New investors can also look for buying opportunities in dips.
Above views are of the author and not of the website kindly read disclaimer
.jpg)
Tag News
We anticipate immense potential benefits from the upcoming Sovereign Gold Bond Tranche in FY...
